Enovis Corporation logo ENOV - Enovis Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 10
HOLD 3
SELL 0
STRONG
SELL 0
| PRICE TARGET: $42.00 DETAILS
HIGH: $52.00
LOW: $30.00
MEDIAN: $45.00
CONSENSUS: $42.00
UPSIDE: 65.62%

Stock News

Enovis Corporation: Arvis Is Disrupting The Health Care Industry

Enovis Corporation: Arvis Is Disrupting The Health Care Industry

Enovis Corporation is rated a buy, trading at a 7x EBITDA multiple versus a sector median of 14.7x, with significant upside if Arvis succeeds. Arvis, a zero-footprint, wearable augmented reality device for orthopedic surgery, targets the fast-growing ambulatory surgery center market and recently achieved full commercialization. ENOV's fundamentals are weak—slim margins, high leverage, and thin free cash flow—but these are already priced in, while Arvis's growth potential is not.

Aug 21, 2026 06:22 AM • seekingalpha.com
Enovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man's Land

Enovis: Executing Better, But Still Remains Stuck In A Med-Tech No Man's Land

Enovis is gaining share in joint reconstruction, leveraging new products and capitalizing on competitor disruptions. Q2 results beat expectations, with 4% organic revenue growth and improved margins, but guidance now anticipates a more Q4-weighted second half. ENOV is making progress on cash flow conversion and deleveraging, and should reach sub-2.0x net debt/EBITDA within three years.

Aug 20, 2026 06:39 AM • seekingalpha.com
Head-To-Head Review: Odyssey Health (OTCMKTS:ODYY) & Enovis (NYSE:ENOV)

Head-To-Head Review: Odyssey Health (OTCMKTS:ODYY) & Enovis (NYSE:ENOV)

Odyssey Health (OTCMKTS:ODYY - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Institutional and Insider Ownership 98.5% of Enovis shares are

Aug 12, 2026 11:33 PM • defenseworld.net
Enovis (NYSE:ENOV) vs. ADB International Group (OTCMKTS:EQUR) Financial Comparison

Enovis (NYSE:ENOV) vs. ADB International Group (OTCMKTS:EQUR) Financial Comparison

Enovis (NYSE: ENOV - Get Free Report) and ADB International Group (OTCMKTS:EQUR - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Earnings and Valuation This table compares Enovis and

Aug 09, 2026 12:01 AM • defenseworld.net
Enovis Q2 Earnings Call Highlights

Enovis Q2 Earnings Call Highlights

Enovis NYSE: ENOV reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Performance & Recovery segment. Management said the company's results reflected improved commercial execution, new-product adoption and operational productivity, while also noting pressure from Middle East-related disruptions and higher inflation.

Aug 07, 2026 10:04 PM • marketbeat.com
Enovis Announces Second Quarter 2026 Results

Enovis Announces Second Quarter 2026 Results

Second-quarter sales growth of 3% on a reported basis, 5% organic Second-quarter Reconstructive sales grew 8% on a reported basis, 6% organic Reaffirmed full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion Dallas, TX, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

Aug 06, 2026 02:05 AM • globenewswire.com
Enovis to Host Second Quarter 2026 Results Conference Call on August 6th

Enovis to Host Second Quarter 2026 Results Conference Call on August 6th

Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2026 financial results on Thursday, August 6th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com.

Jul 17, 2026 04:00 AM • globenewswire.com
Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care

DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients.

Jul 13, 2026 04:30 AM • globenewswire.com
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens

Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens

The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient compliance in adolescent idiopathic scoliosis

Jun 08, 2026 04:30 AM • globenewswire.com

Price Targets